title: MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance.
abstract: BACKGROUND
  The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer.
  
  
  METHODS
  Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells.
  
  
  RESULTS
  Docetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001).
  
  
  CONCLUSIONS
  Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
authors.forename: Yuemeng
authors.initials: Y
authors.lastname: Dai
authors.forename: Cheng-Hui
authors.initials: CH
authors.lastname: Xie
authors.forename: John P
authors.initials: JP
authors.lastname: Neis
authors.forename: Chun-Yang
authors.initials: CY
authors.lastname: Fan
authors.forename: Emre
authors.initials: E
authors.lastname: Vural
authors.forename: Paul M
authors.initials: PM
authors.lastname: Spring
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002277:Carcinoma / Q000188:drug therapy / Q000235:genetics; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor / Q000187:drug effects; D000077143:Docetaxel; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy / Q000235:genetics; D010597:Pharmacogenetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D000077195:Squamous Cell Carcinoma of Head and Neck; D043823:Taxoids / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; D043823:Taxoids; D000077143:Docetaxel